CVS Health Corporation’s Stock Price Drops to $49.58, Suffers 4.21% Decline: Time to Sell?

CVS Health Corporation (CVS)

49.58 USD -2.18 (-4.21%) Volume: 21.36M

CVS Health Corporation’s stock price stands at 49.58 USD, experiencing a trading session dip of -4.21%, with a trading volume of 21.36M. The stock has seen a significant decline YTD, with a percentage change of -37.21%, reflecting its volatile market performance.

Latest developments on CVS Health Corporation

Today, CVS Health Corp’s stock price is facing significant movements as healthcare stocks fall amidst lawmakers pushing for a bill to break up drug middlemen. This comes after bipartisan legislation was introduced to force insurers and PBMs to sell pharmacy businesses, impacting companies like CVS. With Select Health planning to stop covering prescriptions from CVS by 2025 and House Republicans launching an antitrust investigation into CVS Caremark, the industry is facing challenges. Analysts warn that PBM legislation could slash earnings by 50%, leading to CVS hitting an 11-year low. As lawmakers aim to break up health care giants with new legislation, CVS stock has touched a 52-week low of $52.7. Retail pharmacies are struggling while the power of PBMs remains strong, impacting investor sentiment. With ongoing developments, the future of CVS Health Corp’s stock price remains uncertain.

CVS Health Corporation on Smartkarma

Analysts at Baptista Research on Smartkarma have provided insightful coverage on Cvs Health Corp. In their report titled “CVS Health Corporation: Expansion & Optimization of Health Services As A Critical Factor Driving Growth! – Major Drivers”, they highlighted the company’s third-quarter 2024 earnings report, showing a 6% increase in revenue to approximately $95.4 billion. However, challenges were noted in the adjusted earnings per share (EPS) of $1.09, particularly within the Health Care Benefits (HCB) segment.

Another report by Baptista Research on Smartkarma, titled “CVS Health Corporation: Strategic Leverage in Pharmacy Benefit Management (PBM) and Insurance Operations! – Major Drivers”, discussed the mixed financial results of CVS Health in the second quarter of 2024. The company achieved an adjusted earnings per share of $1.83 and revenues exceeding $91 billion, supported by a strong performance in the Health Services and Pharmacy & Consumer Wellness segments. Analysts have shown a bullish sentiment towards the company’s strategic direction and operational achievements.

A look at CVS Health Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CVS Health Corp seems to have a positive long-term outlook. With high scores in Value and Dividend, the company is viewed favorably in terms of its financial health and ability to provide returns to investors. However, its scores in Growth, Resilience, and Momentum are slightly lower, indicating some areas of concern for potential growth and market performance. Overall, CVS Health Corp’s diverse offerings in pharmacy health care services position it well in the market.

CVS Health Corporation is an integrated pharmacy health care provider with a strong focus on pharmacy benefit management services, retail pharmacy, and disease management programs. The company operates numerous drugstores across the U.S., providing a wide range of health care services to customers. Despite facing some challenges in terms of growth and market momentum, CVS Health Corp’s high scores in Value and Dividend reflect its stability and attractiveness to investors looking for long-term returns.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma